| First Author | Year | n | Duration (weeks) | Permitted Co-therapies | Interventions and Control | Quality Score |
| :----------- | :--- | :---- | :--------------- | :----------------------------------------------------------------------------------------- | :---------------------------------------------------------------------------------------------------------------------------------------------------- | :------------ |
| Chan²⁷ | 2007 | 913 | 52 | Stable oral steroids,* stable inhaled steroids, theophylline, non-bronchodilator mucolytic preparations | Tiotropium 18 μg daily<br>Placebo | 4 |
| Dusser²⁵ | 2006 | 1,010 | 48 | Short-acting β agonists, stable oral steroids,* stable inhaled steroids | Tiotropium 18 μg daily<br>Placebo | 3 |
| Freeman²⁸ | 2007 | 395 | 13 | NA | Tiotropium 18 μg daily<br>Placebo | 4 |
| Johansson²⁹ | 2008 | 224 | 13 | Salbutamol, oral steroids, and theophylline only for exacerbations | Tiotropium 18 μg daily<br>Placebo | 3 |
| Moita³⁰ | 2008 | 311 | 13 | Salbutamol, long-acting β agonists, theophylline, mucolytics, stable oral steroids,* stable inhaled steroids | Tiotropium 18 μg daily<br>Placebo | 4 |
| Niewoehner²⁴ | 2005 | 1,829 | 26 | Any (except for other open-label anticholinergic bronchodilators) | Tiotropium 18 μg daily<br>Placebo | 4 |
| Tashkin¹⁴ | 2008 | 5,993 | 208 | Any (except other inhaled anticholinergic bronchodilators) | Tiotropium 18 μg daily<br>Placebo | 4 |
| Tonnel³¹ | 2008 | 554 | 39 | Salbutamol, stable theophylline, stable mucolytics, stable oral steroids,* stable inhaled steroids | Tiotropium 18 μg daily<br>Placebo | 5 |
| Verkindre²⁶ | 2006 | 100 | 13 | Salbutamol, theophylline, stable oral steroids,* inhaled steroids | Tiotropium 18 μg daily<br>Placebo | 3 |
| Vogelmeier³² | 2008 | 847 | 26 | Salbutamol, stable inhaled steroids | Tiotropium 18 μg + Formoterol 10 μg twice daily<br>Placebo twice daily<br>Tiotropium 18 μg + formoterol 10 μg twice daily | 5 |
| Voshaar³³ | 2008 | 719 | 13 | Salbutamol, stable theophylline, stable mucolytics, stable oral steroids,* stable inhaled steroids | Tiotropium 5μg + placebo 4 times daily<br>Tiotropium 10 μg + placebo 4 times daily<br>Ipratropium 36 μg 4 times daily<br>Placebo daily | 4 |

* At a dose of ≤ 10 mg/day prednisone or equivalent
NA = not applicable

Table 2. Patients demographic characteristics of selected studies

| First Author | Year | Age (mean ± SD y) | Male (%) | Current Smoker (%) | Smoking History (mean ± SD pack-years) | COPD Duration (mean ± SD y) | FEV₁/FVC (mean ± SD %) | FEV₁ (mean ± SD % predicted) |
| :----------- | :--- | :---------------- | :------- | :----------------- | :------------------------------------- | :-------------------------- | :----------------------- | :-------------------------- |
| Bruscasco²¹ | 2003 | 64.2 ± 8.4 | 76.3 | NA | 43.8 ± 23.2 | 9.6 ± 7.6 | 43 ± 10 | 39 ± 12 |
| Casaburi¹⁹ | 2002 | 65.0 ± 9.0 | 64.7 | NA | 61.0 ± 30.5 | 8.4 ± 7.1 | 46 ± 12 | 34 ± 12 |
| Casaburi²³ | 2005 | 66.6 ± 7.9 | 56.5 | 24.0 | 58.7 ± 33.0 | 9.3 ± 7.1 | 43 ± 11 | 39 ± 14 |
| Chan²⁷ | 2007 | 66.9 ± 8.9 | 60.0 | 31.0 | 50.6 ± 24.5 | 9.9 ± 8.9 | 46 ± 12 | 39 ± 14 |
| Dusser²⁵ | 2006 | 64.8 ± 9.3 | 88.0 | 25.5 | NA | 8.4 ± 7.8 | 55 ± 12 | 48 ± 13 |
| Freeman²⁸ | 2007 | 64.9 ± 9.1 | 54.3 | NA | 37.4 ± 17.3 | NA | 56 ± 10 | 49 ± 11 |
| Johansson²⁹ | 2008 | 61.6 ± 8.3 | 48.0 | 60.0 | 31.5 ± 12.1 | 4.8 ± 4.2 | 62 ± 7 | 73 ± 13 |
| Moita³⁰ | 2008 | 64.3 ± 8.7 | 94.5 | NA | 56.0 ± 23.6 | 12.4 ± 9.2 | 46 ± 12 | 41 ± 14 |
| Niewoehner²⁴ | 2005 | 67.9 ± 8.6 | 99.0 | 30.0 | 68.4 ± 36.0 | 12.1 ± 10.5 | 48 ± 11 | 36 ± 13 |
| Tashkin¹⁴ | 2008 | 64.5 ± 8.4 | 74.7 | 29.6 | 48.7 ± 28.0 | 9.8 ± 7.5 | 42 ± 11 | 35 ± 14 |
| Tonnel³¹ | 2008 | 64.2 ± 9.9 | 86.0 | 27.0 | 43.7 ± 21.9 | 8.0 ± 7.8 | 55 ± 11 | 47 ± 13 |
| Verkindre²⁶ | 2006 | 60.4 ± 9.9 | 94.0 | 28.5 | 43.7 ± 20.6 | 9.3 ± 6.8 | NA | 35 ± 9 |
| Vogelmeier³² | 2008 | 62.6 ± 8.9 | 77.9 | NA | 38.0 ± 19.6 | 7.0 ± 6.4 | 54 ± 10 | 51 ± 11 |
| Voshaar³³ | 2008 | 64.0 ± 8.8 | 69.3 | 39.3 | 51.0 ± 29.0 | 9.8 ± 7.8 | 48 ± 12 | 41 ± 12 |

FVC = forced vital capacity
NA = no data available

Fig. 2. Effects of tiotropium versus placebo on health-related quality of life, measured with St George's Respiratory Questionnaire.

이 그림은 St George's Respiratory Questionnaire를 사용하여 측정한 건강 관련 삶의 질에 대한 티오트로피움과 위약의 효과를 보여주는 포레스트 플롯입니다.
표는 'Author, Year', 'Tiotropium (n/N)', 'Placebo (n/N)', 'Clinically Important Change in SGRQ' 섹션 아래에 'OR (95% CI)'과 'Weight %*' 열을 포함합니다.
개별 연구 결과는 다음과 같습니다:
- Bruscasco²¹ 2003: Tiotropium (174/356), Placebo (128/326), OR 1.48 (1.09–2.00), Weight 16.20
- Casaburi¹⁹ 2002: Tiotropium (248/507), Placebo (98/325), OR 2.22 (1.65–2.98), Weight 16.91
- Chan²⁷ 2007: Tiotropium (322/608), Placebo (134/305), OR 1.44 (1.09–1.89), Weight 18.18
- Tashkin¹⁴ 2008: Tiotropium (849/1887), Placebo (593/1648), OR 1.46 (1.27–1.67), Weight 32.52
- Tonnel³¹ 2008: Tiotropium (146/247), Placebo (118/245), OR 1.56 (1.09–2.22), Weight 13.14
- Verkindre²⁶ 2006: Tiotropium (26/44), Placebo (16/46), OR 2.71 (1.15–6.36), Weight 3.06
Subtotal (95% CI)는 Tiotropium 총 3649명, Placebo 총 2895명으로, OR 1.61 (1.38–1.88) 및 Weight 100을 나타냅니다.
총 이벤트: Tiotropium (1765), Placebo (1087).
전반적인 (I-squared)는 41.6%, P = .13입니다.
이질성 카이제곱은 8.56 (df = 5)입니다.
전반적인 효과에 대한 테스트는 Z = 6.01, P < .001입니다.
포레스트 플롯의 x축은 1을 기준으로 "Favors Placebo"와 "Favors Tiotropium"을 보여줍니다. 전체 결과는 티오트로피움에 유리하게 나타납니다.

* Weights are from random effects analysis

<PAGE>103